GSK vs AMRN
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Nov 04, 2026
GSK
AMRN
Investment Advisor Scores
AMRN
AI Analyst Insights
Detailed Metrics Comparison
| Metric | GSK | AMRN | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 9.7943 | 500 | GSK |
| PEG Ratio | 6.1233 | 0.8093 | AMRN |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 4.0% | -20.4% | GSK |
| Earnings Growth | -22.8% | -94.2% | GSK |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 47.3/100 | 39.9/100 | GSK |
| Profit Margin | 13.0% | -10.9% | GSK |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | AVOID NEW MONEY | GSK |
Relative Price Performance (Last 90 Days)
Current Technical Phase
GSK
DistributionPrice near a flattening SMA50 (slope -2.2%) with fading momentum, RSI 47
AMRN
NeutralMixed signals - no dominant trend phase, RSI 46
Fundamentals Snapshot
| Metric | GSK | AMRN |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 9.8 | -200.8 |
| Trailing P/E | 17.1 | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | -0.2% |
| Gross Margin | 0.7% | 0.4% |
| Operating Margin | 0.3% | -0.1% |
| EPS | 2.87 | -0.80 |
| Dividend Yield | 0.04% | — |